Table 3 : The influence of HCV genotyping on the outcome response of both regimens studied.

Genotype/ subtype Responders(%) Non-responders(%)
INF  PEG INF INF  PEG INF
ETR SVR ETR SVR ETR SVR ETR SVR
Genotype 1a 0 0 9 5 3 3 2 6
                1b 3 1 14 7 7 9 13 20
                 1UC* 5 3 14 6 6 8 4 12
Genotype 2a 0 0 1 1 1 1 0 0
                2b 0 0 1 0 0 0 0 1
                 2c 0 0 2 0 0 0 0 2
                 2a/c 0 0 0 0 1 1 1 1
                 2UC 9 4 10 5 2 7 2 7
Genotype 3a 2 1 1 1 0 1 1 1
                3UC 9 4 10 6 10 15 4 8
Genotype 4a 4 3 4 1 2 3 4 7
                4c/d 0 0 4 3 1 1 3 4
                4UC 14 8 28 16 7 13 11 23
Total 46(65.7) 24(34.3) 98(65.8) 51(34.2) 40(39.2) 62(60.7) 45(61.7) 92(67.2)

*UC; Unclassified, ETR; End treatment response, SVR; sustained virological response.

A Daw et al.Virology Discovery  2013 1:3DOI : 10.7243/2052-6202-1-3